CHICAGO, March 16, 2021—Vyaire Medical today announced the launch of the AioCare (HealthUp SA, Poland) mobile spirometry system in more than 15 countries across Europe, the Middle East, and Australia. This clinically proven technology expands upon Vyaire’s deep respiratory diagnostics expertise and allows physicians to promptly diagnose pulmonary diseases including asthma and COPD as accurately as hospital-grade spirometers. It also performs high-quality patient monitoring via advanced digital connectivity at home.
“At Vyaire we are committed to advancing respiratory care, delivering new innovation that expands the clinician’s ability to diagnose and treat breathing disorders,” said Gaurav Agarwal, chief executive officer of Vyaire. “The AioCare mobile spirometry system is the latest example of our determination to enhance patients’ lives with new, easy-to-use technology that offers digitally-connected monitoring and care for chronic respiratory diseases in the comfort of their homes.”
“Early diagnosis of COPD is critical to preventing disease escalation and maintaining patients’ quality of life, but many general practitioners and primary care physicians find it difficult to diagnose. AioCare’s algorithm guides physicians and provides them with confidence,” said Michael Pedro, M.D., vice president and medical director of Vyaire. “Further, at-home monitoring is critical for providing patients safe and continuous care at home, particularly now in the midst of the COVID-19 pandemic.”
AioCare consists of a portable spirometer connected to a dedicated smartphone app and an online panel that allows physicians and patients to share and discuss results through remote tracking and secure communication. Dedicated algorithms measure lung parameters and symptoms and provide real-time results, allowing chronic respiratory patients to avoid unexpected consequences of disease exacerbation when self-monitoring. The AioCare digital health technology will also integrate with Vyaire’s SentrySuiteTM software platform, offering healthcare providers more context and information about each patient’s unique respiratory condition.
Worldwide, an estimated 251 million COPD patients and 339 million asthma patients are undiagnosed. Asthma and COPD put enormous economic burdens on healthcare systems across the globe. Having the right tools to assist in early diagnosis and ongoing treatment are critical to reducing those costs.
Under the agreement with HealthUp SA, Vyaire will begin distributing AioCare in the first 15 countries this month, with additional market registrations pending.
About Vyaire Medical
Vyaire Medical Inc. is a global company focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance and extend lives. At Vyaire, we pledge to advance innovation and evolve what's possible to ensure every breath is taken to its fullest. Headquartered in suburban Chicago, Vyaire is recognized, trusted and preferred by specialists throughout the respiratory community worldwide.
Please note that all products, services, or features of products and services may not be available in your local area. Please check with your local Vyaire representative.